Pliant Therapeutics to Participate in the Stifel Healthcare Conference

Rhea-AI Summary

Pliant Therapeutics (Nasdaq: PLRX) announced its participation in the upcoming Stifel 2024 Healthcare Conference. Chief Financial Officer Keith Cummings, M.D., and Greg Cosgrove, M.D. FCCP, will engage in a fireside chat on Tuesday, November 19, 2024, at 8:35 a.m. Eastern Time. The event will take place at the Lotte New York Palace Hotel in New York.

A live webcast will be available through Pliant's website Investor Relations' Events & Presentation page, with a replay accessible for 30 days after the event.

SOUTH SAN FRANCISCO, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), today announced that Keith Cummings, M.D., Chief Financial Officer, and Greg Cosgrove, M.D. FCCP, will participate in a fireside chat at the Stifel 2024 Healthcare Conference on Tuesday, November 19, 2024, at 8:35 a.m. Eastern Time at the Lotte New York Palace Hotel in New York, New York.

Interested parties may access the live webcast of the fireside chat by visiting the Investor Relations’ Events & Presentation page of Pliant’s website. The webcast replay will be archived on the Pliant website for 30 days following the conclusion of the event.

About Pliant Therapeutics, Inc.

Pliant Therapeutics is a late-stage biopharmaceutical company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases. Pliant's lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of αvß6 and αvß1 integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. Bexotegrast has received Fast Track Designation and Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) in IPF and PSC and Orphan Drug Designation from the European Medicines Agency in IPF and PSC. Pliant has initiated BEACON-IPF, an adaptive Phase 2b/3 trial of bexotegrast in IPF. Pliant is conducting a Phase 1 study for its third clinical program, PLN-101095, a small molecule, dual-selective inhibitor of αvß8 and αvß1 integrins, that is being developed for the treatment of solid tumors. In addition, Pliant has received regulatory clearance for the conduct of a Phase 1 study of PLN-101325, a monoclonal antibody agonist of integrin α7β1 targeting muscular dystrophies.

For additional information, please visit: www.PliantRx.com. Follow us on social media: X, LinkedIn, and Facebook.

Investor and Media Contact:

Christopher Keenan
Vice President, Investor Relations and Corporate Communications
Pliant Therapeutics, Inc.
ir@pliantrx.com

FAQ

When is Pliant Therapeutics (PLRX) presenting at the Stifel Healthcare Conference 2024?

Pliant Therapeutics will present at the Stifel Healthcare Conference on Tuesday, November 19, 2024, at 8:35 a.m. Eastern Time.

Where can I watch Pliant Therapeutics' (PLRX) Stifel Conference presentation?

The presentation can be accessed through the live webcast on Pliant's website Investor Relations' Events & Presentation page, with replay available for 30 days after the event.

Who will represent Pliant Therapeutics (PLRX) at the Stifel 2024 Healthcare Conference?

Keith Cummings, M.D., Chief Financial Officer, and Greg Cosgrove, M.D. FCCP, will represent Pliant Therapeutics at the conference.

Where is the Stifel Healthcare Conference 2024 being held for Pliant Therapeutics (PLRX)?

The conference will be held at the Lotte New York Palace Hotel in New York, New York.